TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Estimated intraoperative blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement of FMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Improvement in ACD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: VAS score difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HCAHPS scores for nursing communication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall hospital rating
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Vaginal tears
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of the second period of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in anxiety disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interference from anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in behavioral inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DHEA and androstenedione levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean change on 17-item Hamilton Depression Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimated probability of remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ox-LDL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Osteopenia and osteoporosis incidence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician's Global Assessments of improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Exercise time on the graded exercise test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum amylase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Urine amylase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: duration of the exercise test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients exposed to allogeneic red blood cell transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of red blood cell units transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Postprocedure abdominal pain
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in VSCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall clinical efficacy (cure and improvement combined)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean serum triglyceride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LDL subfraction distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: symptomatic CAUTI incidence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: bacteriuria incidence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Effective rate of physical signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolism of probe drugs mediated by CYP enzymes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cholesterol-lowering drug doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ED visit rates
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Indwelling time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Off-bed time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nursing frequency
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Occurrence of post-operative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Thermal injury at the camera trocar incision
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of patients with mean diurnal IOP <18 mm Hg and short‐term IOP fluctuation ≤2 mm Hg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Percentage of patients with mean IOP <18 mm Hg and long‐term IOP fluctuation ≤2 mm Hg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Mouth-opening values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of disability progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HbA1c after 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Scar appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV-1 DNA copies/10(6) PBMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Provirus-infected cell counts/10(6) PBMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Treatment effectiveness for PWS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scarring occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Patient recovery preference
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: minute ventilation (VI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mean inspiratory flow (VT/TI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: respiration rate (RR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Elbow flexor voluntary activation capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness off AAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Serious procedure and/or device‐related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: ADHD-RS-IV total score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attack rate of Pneumocystis carinii pneumonia (PCP)
Endpoint domain: Mortality/survival
Primary endpoint: Pulmonary function testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of drug toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Urinary hesperetin excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Asthma control rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endoscopic Lund‐Kennedy score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laryngeal preservation rates
Endpoint domain: Mortality/survival
Primary endpoint: skin lifting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: skin radiance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: skin yellowishness reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean pain scores during the first void
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean pain scores after the first void
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reported levels of urgency after cystoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interanalyzer reproducibility for haze measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Eosinophil counts in sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Eosinophil counts in postallergen biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IgE+ cells in biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reoperations due to loss of reduction, nonunion or avascular necrosis
Endpoint domain: Adverse events/effects
Primary endpoint: maximum change in L-Dex value from pretreatment of ≥7.0 L-Dex units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Risk of low-grade prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: increase in blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in THRR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of thrombophlebitis
Endpoint domain: Adverse events/effects
Primary endpoint: Total complications
Endpoint domain: Adverse events/effects
Primary endpoint: start-to-delivery interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of oxytocin required
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of self-reported symptoms of attention, impulsivity, and emotional control
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: 3-D wear rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of osteolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: revision rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: bone turnover markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HbA(1c) levels as a predictor of future diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: time until the first analgesic supplementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of supplementary analgesics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endometrial pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in lifestyle behaviors contributing to coronary heart disease risk
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Response to intravitreal ranibizumab therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of ptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for ocularists' treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: WLpeak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T2DM remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak levels of vaccinia-specific interferon (IFN)-gamma-producing T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Vaccinia-specific CMI responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of musculoskeletal disorders (MSD) in lower extremities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prevalence of musculoskeletal disorders (MSD) in wrist and finger
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cardiac index (CI) after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lactate production after the IP protocol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: reconsultation rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maternal oxytocin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Needle visibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in occurrence of severe and moderate OOP events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of NE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plasma concentrations of E
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: BIS arousal reactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transfusion-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Transfusion- and severe anemia-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Disadvantageous eating styles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intuitive eating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative 12-week incidence of symptom relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement rates of ODI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra‐operative blood loss volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-treatment binge abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pg-Paco2 gap
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric intramucosal pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean serum LDL cholesterol concentrations at 5 years of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean serum cholesterol values between 13 and 60 months of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum IGF‐1 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transthyretin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erythrocyte DHA concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma iron levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in relative contrast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Localization of gross tumor volume (GTV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower odds of drinking more than 400 mL of sugar‐sweetened beverages per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lower snack intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Higher vegetable intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Severity, frequency and duration of vertigo spells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of TUNEL-positive myocytes in DCM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in individual knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: pain and disability reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VNRS pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VNRS 'Bother' scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Request for additional analgesia
Endpoint domain: Adverse events/effects
Primary endpoint: growth of grammar
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of motion sickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abnormal gastric activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: reductions in clinical severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: remission responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Unified Parkinson's Disease Rating Scale motor score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Akinesia subscore
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Axial motor signs subscore
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlations with the FR for nutrients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost-effectiveness of nutritionist review
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: self-reported social anxiety severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinician-rated social anxiety severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pretreatment hypermetabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pulmonary function improvement (FEF25-75)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pulmonary function improvement (FEF50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pulmonary function improvement (FEF75)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: guideline compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10 year coronary heart disease risk reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: myocardial infarction risk reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cardiovascular disease death risk reduction
Endpoint domain: Mortality/survival
Primary endpoint: clinically relevant bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: annualized bleeding rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thermic effect of food
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cumulative fat oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glycemic response to glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Duration of effectiveness per application
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of applications per procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal moisture, clarity, and transparency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left ventricular internal dimension systole (LVIDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left ventricular internal diastolic dimension (LVIDD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: insulin to glucose ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean AAI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reductions in reported worry
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incremental utility of adding rehabilitation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Safety and tolerability of POL6014
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax of POL6014 in subjects with CF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: >1-log reduction of active NE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Screening frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ct positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total oxycodone and APAP exposures (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma concentration for oxycodone and APAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maximum observed plasma concentration of oxycodone and APAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total area under the curve (AUC) for midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oral clearance of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes